高氧血症对成人患者神经功能结局的影响:系统评价与Meta分析
该研究系统检索MEDLINE、Embase、Scopus、Web of Science、CINAHL及ClinicalTrials.gov自建库至2020年5月、将动脉血氧分压(PaO2)与成人急性病住院患者神经功能状态相关联的观察性研究,排除慢性肺疾病或高压氧治疗研究。共筛查6255条记录,纳入32项研究;采用随机效应模型汇总相对危险度(RR),比较高氧血症与无高氧血症患者发生不良神经功能结局的风险。结果显示,高氧血症与不良神经功能结局风险升高显著相关(RR 1.13,95%CI 1.05-1.23,I²=58.8%,22项研究),敏感性分析结果稳健;结局不良者的最大PaO2(SMD 0.17,95%CI 0.04-0.30,I²=78.4%,15项研究)和平均PaO2(SMD 0.25,95%CI 0.04-0.45,I²=91.0%,13项研究)均显著更高。该关联在蛛网膜下腔出血(RR 1.34,95%CI 1.14-1.56)和缺血性卒中(RR 1.41,95%CI 1.14-1.74)中明显,而在心脏骤停、创伤性颅脑损伤或体外循环术后患者中未观察到。作者认为研究不能确立因果关系,但应密切监测PaO2。
要点
- 高氧血症与成人不良神经功能结局风险升高相关:RR 1.13(95%CI 1.05-1.23),I²=58.8%,共22项研究。
- 结局不良患者的最大PaO2更高(SMD 0.17,95%CI 0.04-0.30,I²=78.4%,15项研究),平均PaO2也更高(SMD 0.25,95%CI 0.04-0.45,I²=91.0%,13项研究)。
- 关联在蛛网膜下腔出血(RR 1.34,95%CI 1.14-1.56)和缺血性卒中(RR 1.41,95%CI 1.14-1.74)中明显。
- 在心脏骤停、创伤性颅脑损伤或体外循环术后患者中未观察到该关联。
- 作者认为研究不能确立因果关系,但高氧血症可能影响患者结局和生活质量,应密切监测PaO2。
适用人群与场景
- 因急性疾病住院的成人患者,其动脉血氧分压(PaO2)与神经功能状态相关性的观察性研究人群
- 排除慢性肺疾病研究及高压氧治疗研究
研究设计与关键结果
- 系统评价与Meta分析,检索MEDLINE、Embase、Scopus、Web of Science、CINAHL及ClinicalTrials.gov自建库至2020年5月的观察性研究,筛查6255条记录,最终分析32项研究。
- 高氧血症与不良神经功能结局风险升高显著相关:RR 1.13(95%CI 1.05-1.23),I²=58.8%,22项研究;敏感性分析结果稳健。
- 结局不良患者最大PaO2更高:SMD 0.17(95%CI 0.04-0.30),I²=78.4%,15项研究;平均PaO2更高:SMD 0.25(95%CI 0.04-0.45),I²=91.0%,13项研究。
- 亚组中蛛网膜下腔出血患者RR 1.34(95%CI 1.14-1.56)、缺血性卒中患者RR 1.41(95%CI 1.14-1.74)关联明显;心脏骤停、创伤性颅脑损伤或体外循环术后患者未观察到关联。
证据类型、等级与局限
- 证据类型:观察性研究的系统评价与Meta分析;同时进行了敏感性分析、亚组分析以及发表偏倚和偏倚风险评估。
- 局限:作者指出该研究不能确立因果关系。
对床旁实践的改变
- 作者认为,高氧血症可能与患者结局恶化相关并影响生活质量,因此应密切监测PaO2。
- 原文未据此给出推荐
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Hyperoxemia commonly occurs in clinical practice and is often left untreated. Many studies have shown increased mortality in patients with hyperoxemia, but data on neurological outcome in these patients are conflicting, despite worsened neurological outcome found in preclinical studies. To investigate the association between hyperoxemia and neurological outcome in adult patients, we performed a systematic review and meta-analysis of observational studies. We searched MEDLINE, Embase, Scopus, Web of Science, Cumulative Index to Nursing and Allied Health Literature, and ClinicalTrials.gov from inception to May 2020 for observational studies correlating arterial oxygen partial pressure (PaO2) with neurological status in adults hospitalized with acute conditions. Studies of chronic pulmonary disease or hyperbaric oxygenation were excluded. Relative risks (RRs) were pooled at the study level by using a random-effects model to compare the risk of poor neurological outcome in patients with hyperoxemia and patients without hyperoxemia. Sensitivity and subgroup analyses and assessments of publication bias and risk of bias were performed. Maximum and mean PaO2 in patients with favorable and unfavorable outcomes were compared using standardized mean difference (SMD). Of 6255 records screened, 32 studies were analyzed. Overall, hyperoxemia was significantly associated with an increased risk of poor neurological outcome (RR 1.13, 95% confidence interval [CI] 1.05-1.23, statistical heterogeneity I2 58.8%, 22 studies). The results were robust across sensitivity analyses. Patients with unfavorable outcome also showed a significantly higher maximum PaO2 (SMD 0.17, 95% CI 0.04-0.30, I2 78.4%, 15 studies) and mean PaO2 (SMD 0.25, 95% CI 0.04-0.45, I2 91.0%, 13 studies). These associations were pronounced in patients with subarachnoid hemorrhage (RR 1.34, 95% CI 1.14-1.56) and ischemic stroke (RR 1.41, 95% CI 1.14-1.74), but not in patients with cardiac arrest, traumatic brain injury, or following cardiopulmonary bypass. Hyperoxemia is associated with poor neurological outcome, especially in patients with subarachnoid hemorrhage and ischemic stroke. Although our study cannot establish causality, PaO2 should be monitored closely because hyperoxemia may be associated with worsened patient outcome and consequently affect the patient's quality of life.
参考来源
- Hirunpattarasilp C, Shiina H, Na-Ek N, et al. The Effect of Hyperoxemia on Neurological Outcomes of Adult Patients: A Systematic Review and Meta-Analysis. Neurocrit Care. 2022. PMID: 35099713. doi:10.1007/s12028-021-01423-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。